Inovio Pharma (INO) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Maxim Group Upgrades Inovio Pharmaceuticals (INO) to Buy
March 16, 2017 7:28 AM EDTMaxim Group upgraded Inovio Pharmaceuticals (NASDAQ: INO) from Hold to Buy with a price target of $10.00.
Analyst Jason McCarthy highlighted:
Inovio reported YE16 with $35M in revenue (grants, collaborations) and $112M in operating expenses for a net loss of $74M. The company ended the year with $105M in cash. We expect Inovio will continue to receive grant and collaborative revenue in 2017 which will partially offset operating expenses.... More